APA (7th ed.) Citation

LM, S., H, H., MC, L., E, H., H, I., CA, S., . . . SJ, I. (2022). Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nature cancer, 3(9), 1138. https://doi.org/10.1038/s43018-022-00430-w

Chicago Style (17th ed.) Citation

LM, Spring, et al. "Author Correction: Neoadjuvant Study of Niraparib in Patients with HER2-negative, BRCA-mutated, Resectable Breast Cancer." Nature Cancer 3, no. 9 (2022): 1138. https://doi.org/10.1038/s43018-022-00430-w.

MLA (9th ed.) Citation

LM, Spring, et al. "Author Correction: Neoadjuvant Study of Niraparib in Patients with HER2-negative, BRCA-mutated, Resectable Breast Cancer." Nature Cancer, vol. 3, no. 9, 2022, p. 1138, https://doi.org/10.1038/s43018-022-00430-w.